SCHEMBL4187740

SCHEMBL4187740

Clc1cccc(Nc2cncc(-c3cccc4cccnc34)c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.49
BCR P11274 1/20 0.49
PRKCA P17252 1/20 0.49
PRKCD Q05655 1/20 0.49
XDH P47989 1/20 0.47
SLC22A12 Q96S37 1/20 0.47
GRM4 Q14833 3/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
KMT2A Q03164 1/20 0.45
KDR P35968 10/20 0.43
GSK3A P49840 3/20 0.43
GSK3B P49841 3/20 0.43
INSR P06213 2/20 0.43
FGFR2 P21802 3/20 0.43
EGFR P00533 2/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4198986 0.85 EGFR (0.46) MEN1KMT2AKDREGFRKDM4E
SCHEMBL4187426 0.78 ABL1 (0.60) ABL1BCRPRKCAPRKCDXDH
SCHEMBL4162173 0.76 XDH (0.58) ABL1BCRPRKCAPRKCDXDH
SCHEMBL7444875 0.75 BRD4 (0.52) MEN1KMT2AKDRKDM4EL3MBTL1
SCHEMBL4184945 0.74 XDH (0.51) XDHSLC22A12KDRGSK3AGSK3B
SCHEMBL14867541 0.74 KDM4E (0.52) MEN1ALDH1A1KMT2AKDM4ENPC1
SCHEMBL3938396 0.73 L3MBTL1 (0.60) ALDH1A1PDGFRBKDM4ENPC1RAB9A
SCHEMBL15901697 0.73 KDM4E (0.51) GRM4MEN1ALDH1A1KMT2AKDM4E
SCHEMBL3377751 0.72 GRM4 (0.59) ABL1BCRPRKCAPRKCDGRM4
SCHEMBL3954788 0.72 ABL1 (0.58) ABL1BCRPRKCAPRKCDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo BROWN DENNIS M (US) 2019-08-20 US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 US disclosed
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US disclosed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo NEK9, NEK7, NEK3 ABL1 1085/4885BCR 4304/4885PRKCA 1898/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 ABL1 1085/4885BCR 4304/4885PRKCA 1898/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 ABL1 1085/4885BCR 4304/4885PRKCA 1898/4885
US-20090196912-A1 Pyridinylamines PRNP, PLPBP, SNCA ABL1 2775/4885BCR 4551/4885PRKCA 3884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.